Get started
Author

Laura Winter

Gemtuzumab Ozogamicin in Children and Adolescents With De Novo Acute Myeloid Leukemia Improves Event-Free Survival by Reducing Relapse Risk: Results From the Randomized Phase III Children's Oncology Group Trial AAML0531
2014 · Alan S. Gamis, Todd A. Alonzo, et al. · Journal of Clinical Oncology · 503
PDF
Oral outpatient chemotherapy medication errors in children with acute lymphoblastic leukemia
2006 · James A. Taylor, Laura Winter, et al. · Cancer · 86
PDF
A joint international consensus statement for measuring quality of survival for patients with childhood cancer
2023 · Rebecca J. van Kalsbeek, Melissa M. Hudson, et al. · Nature Medicine · 54
PDF
Variation in Prescribing Patterns and Therapeutic Drug Monitoring of Intravenous Busulfan in Pediatric Hematopoietic Cell Transplant Recipients
2012 · Jeannine S. McCune, K. Scott Baker, et al. · The Journal of Clinical Pharmacology · 44
Pegfilgrastim for prevention of chemotherapy‐associated neutropenia in pediatric patients with solid tumors
2009 · Scott C. Borinstein, Jessica Pollard, et al. · Pediatric Blood & Cancer · 23
COG AAML03P1: Efficacy and Safety in a Pilot Study of Intensive Chemotherapy Including Gemtuzumab in Children Newly Diagnosed with Acute Myeloid Leukemia (AML)
2008 · Janet Franklin, Todd Alonzo, et al. · Blood · 20
Long-term outcome after combined kyphoplasty and intraoperative radiotherapy (Kypho-IORT) for vertebral tumors
2020 · Frederic Bludau, Laura Winter, et al. · Radiation Oncology · 16
PDF
Gemtuzumab Ozogamicin (GO) In Children With De Novo Acute Myeloid Leukemia (AML) Improves Event-Free Survival (EFS) By Reducing Relapse Risk – Results From The Randomized Phase III Children’s Oncology Group (COG) Trial, AAML0531
2013 · Alan S. Gamis, Richard Aplenc, et al. · Blood · 13
The Addition of Bortezomib to Standard Chemotherapy for Pediatric Acute Myeloid Leukemia Has Increased Toxicity without Therapeutic Benefit: A Report from the Children's Oncology Group
2016 · Richard Aplenc, Soheil Meshinchi, et al. · Blood · 12
Severe Toxicities During Pediatric Acute Myeloid Leukemia Chemotherapy: A Report From the Children's Oncology Group.
2010 · Lillian Sung, Richard Aplenc, et al. · Blood · 12
Remission Rates In Childhood Acute Myeloid Leukemia (AML) Utilizing a Dose-Intensive Induction Regimen with or without Gemtuzumab Ozogamicin (GO): Initial Results From the Children's Oncology Group Phase III Trial, AAML0531
2010 · Alan S Gamis, Todd A Alonzo, et al. · Blood · 12
Abnormalities Of 12p Are Associated With High-Risk Acute Myeloid Leukemia: A Children’s Oncology Group Report
2013 · Todd A. Alonzo, Robert B. Gerbing, et al. · Blood · 10
Multidimensional Flow Cytometry Significantly Improves Upon the Morphologic Assessment of Post-Induction Marrow Remission Status – Comparison of Morphology and Multidimensional Flow Cytometry; A Report From the Children's Oncology Group AML Protocol AAML0531
2011 · Michael R. Loken, Todd A. Alonzo, et al. · Blood · 9
Diagnostic Value of sST2, VCAM-1, and Adiponectin in Patients with Breast Cancer to Predict Anti-Tumour Treatment-Related Cardiac Events: A Pilot Study
2022 · Stephanie Luise Rosenkaimer, Laura Winter, et al. · Oncology Research and Treatment · 5
Adverse Cardiovascular Effects of Anti-tumor Therapies in Patients With Breast Cancer: A Single-center Cross-sectional Analysis
2022 · STEPHANIE ROSENKAIMER, TINA SIEBURG, et al. · Anticancer Research · 5
Oral out-patient chemotherapy medication errors in children with acute lymphoblastic leukemia
2006 · D. S. Hawkins, J. Taylor, et al. · Journal of Clinical Oncology · 4
Pediatric Hematology-Oncology Case-Based Lecture Series
2012 · Carl Koschmann, Julie Park, et al. · MedEdPORTAL · 3
Author Correction: A joint international consensus statement for measuring quality of survival for patients with childhood cancer
2024 · Rebecca J. van Kalsbeek, Melissa M. Hudson, et al. · Nature Medicine · 2
PDF
High Mortality In Extreme Hyperleukocytosis In Pediatric Acute Myeloid Leukemia: A Report From the Children's Oncology Group.
2010 · Lillian Sung, Todd A. Alonzo, et al. · Blood · 2
Presence of Residual Disease Detected by Multidimensional Flow Cytometry Identifies Patients with AML At High Risk of Relapse – a Report From the Children's Oncology Group,
2011 · Michael R. Loken, Todd A. Alonzo, et al. · Blood · 1
Author Correction: A joint international consensus statement for measuring quality of survival for patients with childhood cancer
2023 · Rebecca J. van Kalsbeek, Melissa M. Hudson, et al. · Nature Medicine
PDF
Author Correction: A joint international consensus statement for measuring quality of survival for patients with childhood cancer
2023 · Rebecca J. van Kalsbeek, Melissa M. Hudson, et al. · Nature Medicine
PDF
Elevated Expression of miR-181a and miR-155 Identify Pediatric AML Patients at High Risk of Induction Failure, A Report from Children's Oncology Group.
2012 · Ranjani Ramamurthy, Todd A. Alonzo, et al. · Blood
Cryptic NUP98/NSD1 Translocations Are Highly Prevalent in FLT3/ITD-Positive Acute Myeloid Leukemia and Lead to High Rate of Induction Failure. Report From Children's Oncology Group
2012 · Fabiana Ostronoff, Todd A. Alonzo, et al. · Blood
Flow Cytometric Assessment of Post Induction Response In Patients with Sub-Optimal Morphologic Response to Induction Chemotherapy- A Report From the Children's Oncology Group AML Protocol AAML0531
2010 · Michael R. Loken, Todd A. Alonzo, et al. · Blood
Works count: 26
Citation count: 836
H-index: 11
I10-index: 12
Year
Topic
Type